Clinical effect of 3g/day administration of meropenem on severe pneumonia

概要

論文の詳細を見る
We examined the clinical effect of Meropenem (MEPM) on severe pneumonia. We administered 3g of Meropenem daily to 20 patients with severe pneumonia: 8 communityacquired pneumonia patients, 9 nursing and healthcare-associated pneumonia patients, and 3 hospital-acquired pneumonia patients. It was effective in 15 of the 20 patients (75%): 8 of 8 community-acquired pneumonia patients (100%), 6 of 9 nursing and healthcare-associated pneumonia patients (66.6%), and 1 of 3 hospital-acquired pneumonia patients (33.3%). Bacteriologically, 9 of a total of 10 strains (90%) were eradicated: 4 of 4 Streptococcus pneumoniae strains, 2 of 2 methicillin-sensitive Staphlococcus aureus strains, 1 of 2 Enterococcus faecalis strains, 1 of 1 Klebsiella pneumoniae strain, and 1 of 1 Escherichia coli strain. Hepatic dysfunction was observed as a side effect in 8 patients (40%). Based on the above, administration of MEPM daily 3 g is extremely effective for community-acquired pneumonia, while it appears ineffective in many cases of nursing and healthcare-associated pneumonia or hospital-acquired pneumonia, and results in hepatic dysfunction at a high frequency.
2013-00-00